Low libido after prostate cancer treatment can come from direct testosterone suppression, treatment-related sexual dysfunction, fatigue, mood changes, body-image changes or relationship strain—and the mechanism matters. Androgen deprivation therapy has the clearest direct biological effect because it intentionally lowers testosterone, a hormone that supports sexual desire. Surgery and radiation can also reduce sexual interest, but often indirectly through erectile dysfunction, dry orgasm, urinary leakage, pain, fatigue or emotional consequences of cancer treatment. Libido should therefore be evaluated separately from erection quality.
Androgen deprivation therapy commonly lowers sexual desire because it suppresses testosterone. EAU guidance states that ADT reduces both libido and the ability to gain or maintain erections, and sexual activity stops in up to 93% of men in some studies. NCI similarly lists loss of interest in sex among the major adverse effects of prostate-cancer hormone therapy. Libido may improve after temporary ADT ends, but recovery depends on testosterone recovery, treatment duration, age, baseline testosterone and other health factors. In randomized long-term data, normal testosterone recovered in about 76% after 6 months of ADT, 55% after 18 months and 43% after 36 months. Low libido that persists after testosterone has recovered should not automatically be blamed on the cancer treatment; broader medical, medication, psychological and relationship causes then deserve evaluation through the main Male Libido pathway.
01What Is Libido, and How Is It Different From Erectile Function?
Libido means sexual desire—not penile rigidity
Low libido means a reduction in:
- sexual interest;
- sexual thoughts or fantasies;
- desire to initiate sexual activity;
- or motivation to respond to sexual cues.
Erectile dysfunction is different.
A man can:
- have strong sexual desire but be unable to achieve an erection;
- have mechanically adequate erections but little or no sexual desire;
- or have both problems at the same time.
That distinction is especially important during prostate cancer treatment because ADT affects desire directly, while prostatectomy and radiation more commonly affect erectile physiology.
Is testosterone the only thing controlling libido?
No.
Testosterone is biologically important for male sexual desire, but libido does not map perfectly to a single serum testosterone value.
EAU sexual-health guidance notes that testosterone is essential for male sexual desire, while also emphasizing that circulating testosterone level does not directly predict desire in every individual—particularly in older men.
What else influences libido?
Relevant factors include:
- depression;
- anxiety;
- relationship conflict or sexual-desire discrepancy;
- fatigue;
- sleep disruption;
- pain;
- poor overall health;
- vascular disease;
- medications such as some antidepressants;
- endocrine disorders;
- erectile dysfunction;
- and beliefs or fears about sexuality after cancer.
Can the diagnosis of prostate cancer itself reduce libido?
Yes.
Sexual desire can change before treatment because a cancer diagnosis can create:
- fear;
- uncertainty;
- depression;
- changes in self-image;
- relationship stress;
- and concern about pain, recurrence or sexual performance.
Therefore, a decline in libido beginning around diagnosis should not automatically be attributed to surgery, radiation or testosterone suppression.
How can surgery affect libido if it does not intentionally lower testosterone?
Radical prostatectomy does not normally remove the testes or intentionally suppress testosterone.
But it can reduce sexual desire indirectly through:
- postoperative erectile dysfunction;
- dry orgasm;
- climacturia;
- painful or altered orgasm;
- urinary incontinence;
- penile/body-image concerns;
- and repeated unsuccessful attempts at sexual activity.
These issues can condition avoidance: sexual interest may fall because sexual activity has become stressful, unpredictable or disappointing.
How can radiation affect libido?
Radiation may affect libido through a combination of:
- fatigue during treatment;
- gradual erectile decline;
- ejaculatory changes;
- bowel or urinary symptoms;
- and concurrent ADT when used.
When radiation is combined with ADT, the hormonal contribution can dominate the sexual-desire change.
Ask two questions, not one: “Do you want sexual activity?” and “Can your body respond when you want it?” The first identifies libido; the second begins the erectile/sexual-function assessment.
02Why Does Androgen Deprivation Therapy Reduce Libido?
ADT intentionally creates a low-testosterone state
Prostate cancer cells usually depend on androgen-receptor signaling.
Androgen deprivation suppresses that pathway by:
- reducing testicular testosterone with GnRH agonists or antagonists;
- or permanently removing the testicular testosterone source with bilateral orchiectomy.
The prostate-cancer benefit comes from the same endocrine change that creates many sexual side effects.
Why is testosterone relevant to sexual desire?
Testosterone helps maintain:
- sexual thoughts;
- spontaneous sexual interest;
- responsiveness to erotic cues;
- and aspects of erectile physiology.
When testosterone falls to castrate levels, libido can drop dramatically.
How common is sexual inactivity during ADT?
Current EAU prostate-cancer quality-of-life guidance states that cessation of sexual activity is very common during ADT and affects up to 93% of men in some studies.
EAU follow-up guidance also notes that more than 80% of couples can cease sexual activity completely after ADT begins.
These figures describe sexual activity—not a pure biochemical measurement of libido—but they show the scale of the sexual impact.
Does ADT affect erections as well as desire?
Yes.
ADT reduces:
- libido;
- spontaneous erections;
- erectile responsiveness;
- and sexual activity.
NCI specifically notes that sildenafil and similar drugs do not usually solve the whole problem during hormone therapy because they address penile blood flow rather than the androgen-driven loss of sexual desire.
Does every man lose libido completely?
No.
Individual response varies.
Some men report:
- complete absence of sexual interest;
- greatly reduced but not absent desire;
- interest in intimacy without interest in intercourse;
- or continued sexual motivation despite weaker physical response.
Age, baseline sexual interest, relationship context, treatment duration, depression, fatigue and other medications can modify the experience.
Does longer ADT usually mean a longer sexual burden?
Yes.
NCI states that many adverse effects become more likely or more persistent the longer androgen deprivation continues.
This is clinically relevant because prostate cancer uses very different ADT durations:
- months with radiation for some intermediate-risk cancers;
- 18–36 months or roughly 2–3 years with high-risk radiation in common guideline frameworks;
- and continuous treatment in many metastatic settings.
The meaning of “low libido on ADT” therefore differs between a temporary six-month course and ongoing metastatic therapy.
What else during ADT can indirectly reduce libido?
ADT can also cause:
- hot flashes;
- fatigue;
- sleep disruption;
- loss of muscle;
- increase in body fat;
- breast tenderness or enlargement;
- mood changes;
- and changes in self-image.
These effects can reduce sexual interest independently of the serum testosterone number.
Can depression be part of the libido problem?
Yes.
EAU follow-up guidance emphasizes mental-health monitoring during ADT and reports that men receiving androgen deprivation are more likely to report depression.
Depression itself is a recognized cause of low sexual desire.
During medically necessary ADT, low libido is an expected treatment effect—not evidence that the treatment is “failing.” The goal is usually to support intimacy, quality of life, mood and relationship adaptation while maintaining the testosterone suppression needed for cancer control.
03Does Libido Return After Androgen Deprivation Therapy Stops?
Libido can improve—but testosterone recovery is often slower than patients expect
The final injection date is not the same as the testosterone-recovery date.
Depot GnRH medications can continue working after the last scheduled dose.
Then the hypothalamic-pituitary-gonadal axis must resume enough function for testosterone to rise.
What do randomized long-term data show?
A 2024 analysis included 1,230 men with localized prostate cancer treated in two randomized phase III radiotherapy trials.
Normal testosterone recovered in:
- 87.4% after 0 months of ADT;
- 75.9% after 6 months;
- 54.8% after 18 months;
- 43.2% after 36 months.
How long did recovery take among men who recovered?
Median time to normal testosterone recovery increased with prescribed ADT duration:
- 1.64 years after 6 months of ADT;
- 3.06 years after 18 months;
- 5.0 years after 36 months.
The study found that:
- longer ADT duration;
- older age;
- abnormal baseline testosterone;
- and medical comorbidity
were associated with less complete or slower recovery.
Does testosterone recovery guarantee libido recovery?
No.
Testosterone recovery removes one major biological barrier, but libido may remain low because of:
- erectile dysfunction;
- relationship changes;
- depression or anxiety;
- fatigue;
- medication effects;
- sleep problems;
- body-image changes;
- or altered sexual routine after years of treatment.
Can libido improve before testosterone reaches a laboratory “normal” range?
Possibly.
Sexual desire is not controlled by one threshold.
Some patients experience gradual return of:
- sexual thoughts;
- morning/spontaneous erections;
- interest in intimacy;
- or improved energy
as testosterone rises, even before a laboratory reports full normalization.
Others reach a normal testosterone range but still have low desire from non-hormonal causes.
Can recovery differ by ADT drug?
Yes.
The pharmacology of the drug matters.
For example, oral relugolix does not create a long-lasting injection depot and has shown faster testosterone recovery than leuprolide in a HERO trial recovery subgroup.
But drug-specific recovery data should not override:
- the cancer indication;
- required duration of suppression;
- adherence;
- cardiovascular considerations;
- and oncologist/urologist treatment planning.
Testosterone recovery is a biological prerequisite for many men—but it is not a guarantee of restored desire. If libido remains low after hormonal recovery, the clinical question should expand beyond prostate cancer into medication, mood, sleep, relationship, endocrine and general-health causes.
04What Can Help Low Libido During or After Prostate Cancer Treatment?
First identify whether testosterone suppression is intentional and still necessary
This is the most important prostate-cancer-specific step.
If ADT is currently being given because it improves cancer control:
raising testosterone to treat libido would work against the oncological treatment goal.
The management focus is therefore on:
- accurate expectations;
- mood and fatigue management;
- relationship adaptation;
- sexual rehabilitation within the patient’s level of desire;
- and reducing avoidable treatment toxicity.
Should ADT be stopped early because libido is low?
Not without oncology/urology review.
ADT duration is selected according to:
- prostate-cancer risk group;
- radiation strategy;
- metastatic status;
- treatment response;
- and evidence for survival or disease-control benefit.
Sexual toxicity is important, but the response is shared decision-making about benefit, duration and alternatives—not self-discontinuation.
Can exercise help libido directly?
Exercise should not be presented as a guaranteed libido treatment.
However, during ADT it can improve several factors that indirectly influence sexual well-being:
- fatigue;
- muscle strength;
- body composition;
- physical confidence;
- metabolic health;
- and overall quality of life.
EAU prostate-cancer guidance strongly supports supervised aerobic and resistance exercise during androgen deprivation to reduce treatment toxicity.
Can erectile treatment restore libido?
Not necessarily.
PDE5 inhibitors, vacuum devices or injections can improve erection mechanics.
They do not directly create sexual desire.
This is why NCI notes that erectile-dysfunction medication may have limited impact when the core problem during ADT is loss of androgen-driven libido.
For prostate-treatment erectile dysfunction, see Erectile Dysfunction After Prostate Cancer Treatment.
What can help couples when desire changes?
Useful strategies can include:
- explicitly discussing whether the goal is intercourse, intimacy, touch or sexual rehabilitation;
- reducing pressure to perform on a fixed schedule;
- allowing sexual activity to change during treatment;
- addressing leakage, pain or erectile difficulties that make sex aversive;
- and using couple-based or psychosexual counseling when treatment has created distress or desire discrepancy.
EAU survivorship guidance recognizes that sexual well-being affects both patients and partners and supports multidisciplinary rehabilitation.
What if libido is still low after ADT has ended?
A prostate-cancer follow-up assessment can consider:
- serum testosterone recovery;
- ongoing cancer status;
- fatigue;
- depression/anxiety;
- medication effects;
- erectile function;
- sleep;
- relationship factors;
- and other endocrine abnormalities when clinically indicated.
If testosterone has normalized, persistent low libido becomes less likely to be explained by androgen deprivation alone.
Can testosterone replacement therapy be used after prostate cancer?
This requires careful nuance.
Testosterone therapy should not be used to reverse libido loss while ongoing androgen deprivation is required for cancer control.
Current 2026 EAU sexual-health guidance states that testosterone therapy is contraindicated in locally advanced or metastatic prostate cancer.
For men with symptomatic hypogonadism after apparently curative treatment, the evidence is more nuanced and long-term safety data remain limited.
What does EAU 2026 say after radical prostatectomy?
EAU recommends caution and restricts consideration to selected men at low risk of recurrent prostate cancer after surgery.
The guideline gives a weak recommendation to:
- wait at least one year after surgery;
- require PSA below 0.01 ng/mL;
- and have no evidence of recurrence
before considering testosterone therapy in this selected setting.
What about men on active surveillance or treated with radiation?
EAU 2026 says safety data are unclear for:
- men on active surveillance;
- and men treated with non-surgical curative-intent therapy.
This does not mean testosterone therapy is automatically forbidden in every survivor.
It means the decision requires:
- confirmed symptomatic testosterone deficiency;
- prostate-cancer risk review;
- PSA status;
- discussion of uncertain long-term oncological safety;
- and specialist monitoring.
Why not use an over-the-counter “testosterone booster”?
Because:
- the active ingredients and doses may be uncertain;
- some products can affect hormones or interact with medications;
- and deliberately increasing androgen activity can conflict with prostate-cancer treatment.
Any hormone-oriented supplement should be reviewed with the treating oncology/urology team.
Do not self-treat ADT-related low libido with testosterone. During androgen deprivation, low testosterone is the intended cancer treatment. After curative therapy, testosterone replacement is a separate specialist decision with cancer-status and PSA requirements.
The target is the cause, not the symptom label. Low libido from active ADT, depression, erectile failure, sleep disruption and true persistent hypogonadism may feel similar to the patient but require very different management.
05Where Does This Prostate-Cancer Libido Page End?
This page owns the treatment-to-libido relationship
The prostate-cancer-specific questions answered here are:
- why ADT lowers libido;
- how libido differs from erectile function;
- why surgery/radiation can lower desire indirectly;
- how treatment duration affects testosterone recovery;
- why libido may lag after ADT ends;
- and why testosterone therapy after prostate cancer requires cancer-specific safety review.
What belongs in the broader Male Libido root?
The Male Libido root should own the general evaluation of low sexual desire, including:
- low desire unrelated to prostate cancer;
- general testosterone deficiency;
- hyperprolactinemia;
- thyroid disorders;
- depression and anxiety;
- antidepressant and medication effects;
- relationship conflict or desire discrepancy;
- sleep and chronic illness;
- and general low-libido treatment options.
Why should prostate cancer not own the full low-libido query?
Because prostate treatment is only one cause of low sexual desire.
EAU sexual-health guidance lists multiple non-cancer causes, including:
- androgen deficiency;
- depression;
- anxiety;
- relationship conflict;
- antidepressant therapy;
- cardiovascular disease;
- renal disease;
- aging;
- and erectile dysfunction.
Once the prostate-specific treatment mechanism has been addressed, continuing the entire differential here would duplicate the broader root.
What is the next prostate-cancer page?
The next contextual page is Biochemical Recurrence After Prostate Cancer Treatment.
That marks an important semantic transition:
from functional survivorship outcomes back to cancer surveillance and recurrence.
Why does biochemical recurrence come next?
After initial treatment, survivorship has two parallel tracks:
- functional recovery—urinary, sexual, fertility and hormonal outcomes;
- and oncological follow-up—PSA surveillance and assessment for recurrence.
R1-E-44 finishes this cluster’s prostate-specific sexual-desire bridge and returns the content path to disease monitoring.
Bridge rule: explain how prostate cancer treatment changed libido here, then hand the broader low-desire differential to Male Libido. The next prostate page should return to oncological surveillance rather than continuing to duplicate sexual-health root content.
→Libido Effects by Prostate Cancer Treatment
| Treatment | Primary effect on libido | Mechanism | Recovery implication |
|---|---|---|---|
| Active surveillance | No direct treatment-related androgen suppression. | Diagnosis-related anxiety, depression, relationship stress or general health can still alter desire. | Persistent low libido should follow the broader Male Libido work-up rather than being assumed to be caused by surveillance. |
| Radical prostatectomy | Libido may fall indirectly. | ED, dry orgasm, climacturia, urinary leakage, altered body image and sexual disappointment. | Desire can improve as function/confidence recover; surgery does not routinely create castrate testosterone. |
| External-beam radiation / brachytherapy | Usually indirect unless ADT is added. | Fatigue, erectile decline, ejaculatory change, urinary/bowel effects; small testicular scatter can occur. | Sexual interest may improve after acute toxicity settles; ADT-related recovery follows testosterone kinetics. |
| Temporary ADT | Strong direct reduction. | Intentional testosterone suppression plus fatigue, hot flashes and body-composition changes. | May improve after stopping, but testosterone recovery can take months to years and can remain incomplete. |
| Continuous ADT | Persistent reduction is common. | Ongoing castrate testosterone. | Management focuses on adaptation and quality of life while cancer-control indication remains. |
| Bilateral orchiectomy | Strong permanent hormonal effect. | Permanent removal of the main testosterone source. | No spontaneous testicular testosterone recovery; hormone decisions depend on cancer status and specialist guidance. |
Key Points
- Libido means sexual desire; it is not the same as erectile function.
- ADT is the prostate-cancer treatment with the clearest direct biological effect on libido because it intentionally suppresses testosterone.
- EAU states that androgen deprivation reduces both libido and erectile function.
- Sexual activity stops in up to 93% of men receiving ADT in some studies.
- NCI lists loss of interest in sex among the major adverse effects of prostate-cancer hormone therapy.
- Erection medication may not restore sexual interest when profound androgen suppression is the main problem.
- Radical prostatectomy can reduce libido indirectly through erectile dysfunction, dry orgasm, climacturia, urinary leakage and psychological adaptation.
- Radiation can reduce sexual interest indirectly through fatigue, erectile/ejaculatory changes and concurrent ADT.
- Testosterone is important for sexual desire, but a serum testosterone value does not perfectly predict libido in every man.
- Depression, anxiety, relationship factors, medications, sleep and chronic disease can coexist with treatment-related libido loss.
- Longer ADT makes normal testosterone recovery less likely and slower.
- In 1,230 randomized-trial participants, normal testosterone recovered in 75.9% after 6 months, 54.8% after 18 months and 43.2% after 36 months of ADT.
- Among those recovering, median time to normal testosterone was 1.64, 3.06 and 5.0 years after 6, 18 and 36 months of ADT, respectively.
- Older age, longer ADT, abnormal baseline testosterone and comorbidities are associated with slower or less complete testosterone recovery.
- Testosterone normalization does not guarantee libido normalization.
- During medically necessary ADT, testosterone should not be raised simply to treat low libido because testosterone suppression is the cancer treatment goal.
- ADT should not be stopped or shortened without oncology/urology review.
- Exercise can improve fatigue, muscle strength, body composition and quality of life during ADT, even though it is not a guaranteed libido treatment.
- Current EAU 2026 guidance says testosterone therapy is contraindicated in locally advanced or metastatic prostate cancer.
- For selected low-recurrence-risk men after radical prostatectomy, EAU gives only a weak recommendation to consider testosterone therapy after at least one year, PSA below 0.01 ng/mL and no evidence of recurrence.
- EAU states that testosterone-therapy safety data remain unclear for men on active surveillance or treated with non-surgical curative intent.
- Persistent low libido after prostate-specific hormonal recovery should transition to the broader Male Libido evaluation.
Clinical bottom line: low libido after prostate cancer treatment should be interpreted according to mechanism. Androgen deprivation directly suppresses sexual desire by lowering testosterone and can cause profound reductions in sexual activity, especially during long treatment courses. Surgery and radiation do not usually suppress testosterone in the same way, but they can reduce desire indirectly through erectile dysfunction, dry orgasm, urinary leakage, pain, fatigue and psychological adaptation. After temporary ADT, libido may return gradually, but testosterone recovery can take years and remains incomplete in a substantial proportion of men after longer treatment. Testosterone replacement is not a simple survivorship fix: it conflicts with active androgen-deprivation treatment and requires careful cancer-status review after curative therapy. Once the prostate-specific treatment mechanism has been addressed, persistent low libido belongs in the broader Male Libido pathway rather than being indefinitely attributed to prostate cancer.
Medical disclaimer: This article provides general medical education about libido specifically after prostate cancer treatment. Sexual desire is influenced by cancer therapy, testosterone, age, medications, mood, sleep, relationship context, general health and other endocrine conditions. Do not start testosterone, “testosterone boosters,” change androgen-deprivation therapy or stop cancer medication because of low libido without review by the treating urology/oncology team.
For the broader prostate-cancer framework, return to the Prostate Cancer hub. The previous survivorship page covers Fertility After Prostate Cancer Treatment. The next contextual page returns to oncological surveillance with Biochemical Recurrence After Prostate Cancer Treatment. For low sexual desire beyond the prostate-cancer-treatment relationship, continue to the broader Male Libido guide.
Evidence Sources
- European Association of Urology — Prostate Cancer Quality of Life Outcomes: effects of ADT on libido, erectile function, sexual activity, partners and survivorship.
- European Association of Urology — Prostate Cancer Follow-up: sexual dysfunction, mental health, fatigue, exercise and partner impact during androgen deprivation.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: loss of libido, erectile dysfunction, duration-dependent adverse effects and limitations of ED medication during profound androgen suppression.
- National Cancer Institute — Sexual Health Issues in Men and Cancer Treatment: hormone therapy, radiation, surgery and treatment-related changes in sexual drive and sexual function.
- Nabid et al., Radiotherapy and Oncology 2024 — testosterone recovery after 0, 6, 18 and 36 months of ADT in 1,230 randomized-trial participants.
- TRANSPORT/MARCAP pooled randomized-trial analysis — testosterone recovery kinetics after androgen suppression and prostate radiotherapy.
- EAU Sexual and Reproductive Health — Low Sexual Desire: testosterone, medical, medication, psychological and relationship causes of low male sexual desire.
- EAU Sexual and Reproductive Health 2026 — Male Hypogonadism: testosterone therapy after prostate cancer, contraindications and long-term safety uncertainty.
- EAU Sexual and Reproductive Health 2026 update — revised prostate-cancer recommendations for testosterone therapy, including low-risk post-prostatectomy selection and PSA requirements.
